The article Mindset Granted Patent for Lead Drug (But Reunion Also Has Patent) was originally published on Microdose.
Mindset Pharma has been granted a U.S. patent for its lead candidate drug, MSP-1014. MSP-1014 and MSP-1009 are novel analogues of psilocybin that demonstrated improved efficacy and safety profiles in pre-clinical studies. Yet, in a patent law twist, Reunion Neuroscience (formerly Field Trip) was already awarded a patent for the same compound in April of […]